Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 2, 2020
-
Oct 29, 2020--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020--
-
Oct 28, 2020-- ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition --
-
Oct 20, 2020
-
Sep 30, 2020- Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 -
-
Sep 16, 2020
-
Sep 9, 2020
-
Sep 7, 2020--New Data from WILLOW Study also Presented During Late-Breaking Session at European Respiratory Society International Congress--
-
Aug 6, 2020--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020--
-
Jul 27, 2020
-
Jul 24, 2020- If Approved, ARIKAYCE Will Be First and Only Therapy in the European Union for This Difficult-to-Treat Condition -
-
Jul 7, 2020--First update to treatment guidelines in more than a decade, marking important milestone in patient care--
-
Jun 24, 2020--Brensocatib Shown to Reduce Time to First Pulmonary Exacerbation and Reduce Rate of Exacerbations Versus Placebo--
-
Jun 8, 2020--Full Results from Phase 2 WILLOW Study of Brensocatib in NCFBE to be Presented at Virtual ATS Session on June 24, 2020--
-
May 26, 2020
-
May 20, 2020Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session-Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis to be Presented-
-
Apr 30, 2020--Company Supports Investigator-Initiated Study of Brensocatib (Formerly INS1007) in Severe COVID-19 and Continues to Advance Development in Bronchiectasis--
-
Apr 23, 2020--Insmed to support STOP-COVID19 Study, Expected to Begin in the UK in May 2020--
-
Apr 20, 2020
-
Mar 16, 2020-- Company Submits New Drug Application in Japan for ARIKAYCE® (amikacin liposome inhalation suspension) for the Treatment of Patients with NTM Lung Disease Caused by MAC --
-
Mar 4, 2020-- Management of common adverse events through physician-guided measures resulted in symptomatic improvement --
-
Feb 25, 2020--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $45.7 Million for the Fourth Quarter 2019 and $136.5 Million for the Full Year 2019--
-
Feb 10, 2020
-
Feb 3, 2020-- Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo --
-
Nov 26, 2019
-
Nov 14, 2019-Drayton Wise named Senior Vice President, Head of U.S.
-
Nov 5, 2019
-
Oct 30, 2019--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $38.9 Million for the Third Quarter of 2019--
-
Oct 23, 2019
-
Sep 3, 2019
-
Aug 1, 2019--ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $29.0 Million for the Second Quarter of 2019--
-
Jul 25, 2019
-
May 20, 2019--ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--
-
May 7, 2019-- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --
-
Apr 30, 2019
-
Apr 9, 2019--Patent is 10th Issued in the U.S. for ARIKAYCE and Second Extending Patent Protection into 2035--
-
Apr 8, 2019--ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019--
-
Apr 1, 2019--Sustainability and Durability Data from Phase 3 CONVERT Study of ARIKAYCE to be Presented in Late-Breaking Oral Session--
-
Mar 27, 2019
-
Feb 22, 2019--ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018--
-
Feb 15, 2019
-
Jan 4, 2019-ARIKAYCE Preliminary Unaudited U.S. Net Product Sales Approximately $9.2 Million for the Fourth Quarter of 2018-
-
Nov 8, 2018—Seasoned Pharmaceutical Executive Elizabeth McKee Anderson Appointed as New Director—
-
Nov 6, 2018
-
Oct 30, 2018—Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch—
-
Oct 23, 2018
-
Oct 4, 2018New Patent Adds 7 ½ Years of Market Exclusivity in Japan
-
Oct 1, 2018
-
Sep 28, 2018Commercial availability expected in early Q4 2018
-
Sep 17, 2018As previously reported, study met primary endpoint of culture conversion (p<0.0001)
-
Aug 27, 2018Advisory committee supports surrogate endpoint of sputum culture conversion
-
Aug 2, 2018PDUFA (Prescription Drug User Fee Act) Action Date for ALIS (Amikacin Liposome Inhalation Suspension) Set for September 28, 2018
-
Jul 26, 2018
-
Jun 15, 2018Meeting planned for August 7, 2018
-
Jun 7, 2018
-
May 22, 2018Data support the benefit of treating patients with a combination of ALIS (Amikacin Liposome Inhalation Suspension) and guideline-based therapy (GBT) for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC)
-
May 17, 2018
-
May 16, 2018PDUFA Action Date Set for September 28, 2018
-
May 2, 2018Submitted NDA to FDA for Amikacin Liposome Inhalation Suspension (ALIS) in NTM lung disease caused by MAC; anticipates priority review
Your Privacy Choices